Non-small cell lung cancer (NSCLC) remains a major cause of morbidity and mortality
worldwide. One-third of NSCLC patients present with surgically resectable, non-metastatic …

Simple Summary Surgical resection remains the gold standard of early-stage non-small cell
lung cancer (NSCLC) treatment. However, only a minority of resected patients remain …

Background Non-small-cell lung cancer (NSCLC) accounts for most new diagnoses of lung
cancer, with high morbidity and mortality worldwide. Immune checkpoint inhibitor (ICI) …

In the last decade, immune-checkpoint inhibitors (ICIs) have become the backbone of
therapy in advanced, non-oncogene driven, non-small cell lung cancer (NSCLC). More …

Methods Relevant articles for this review were retrieved from Google Scholar, Clinicaltrials.
gov., and PubMed using the terms “non-small-cell lung cancer”,“NSCLC”,“neoadjuvant”,“ …

Prognosis of early stage non-small cell lung cancer (eNSCLC) is poor even when treated
radically with surgery and (neo) adjuvant chemotherapy (Cht). The discovery of tyrosine …

Lung cancer continues to be a leading cause of cancer-related death worldwide. Despite
tremendous advances in surgical technique, chemotherapy regimens, radiation, and …

Abstract Purpose of Review For decades, early-stage resectable non-small cell lung cancer
(NSCLC), while potentially curable, has been marred by unacceptably high recurrence …

Background The neoadjuvant use of immune checkpoint inhibitors (ICIs) in resectable non-
small-cell lung cancer (NSCLC) is currently an area of active ongoing research. The place of …

Despite remarkable treatment advancements in patients with advanced non–small cell lung
cancer (NSCLC), recurrence rates for those with resectable, early-stage disease remains …